International trade · 04/08/2016

U.S. International Trade Commission Reviews Certain Recombinant Factor VIII Products

The U.S. International Trade Commission has decided to partially review a 2016 decision that found no infringement of a patent related to recombinant factor VIII products, a key treatment for hemophilia. The review will focus on the economic viability of the domestic industry.